These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22841019)

  • 1. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients.
    Briere TM; Crane CH; Beddar S; Bhosale P; Mok H; Delclos ME; Krishnan S; Das P
    Radiother Oncol; 2012 Aug; 104(2):161-6. PubMed ID: 22841019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
    Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
    Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric Predictors of Radiation-Induced Vaginal Stenosis After Pelvic Radiation Therapy for Rectal and Anal Cancer.
    Son CH; Law E; Oh JH; Apte AP; Yang TJ; Riedel E; Wu AJ; Deasy JO; Goodman KA
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):548-54. PubMed ID: 25936810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
    Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) - a prospective, randomized, 2-armed phase-II-trial.
    Arians N; Häfner M; Krisam J; Lang K; Wark A; Koerber SA; Hommertgen A; Debus J
    BMC Cancer; 2020 Jan; 20(1):52. PubMed ID: 31964381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
    Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
    Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study.
    Elson JK; Kachnic LA; Kharofa JR
    Cancer; 2018 Nov; 124(22):4383-4392. PubMed ID: 30329160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
    Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT.
    Dell'Acqua V; Kobiela J; Kraja F; Leonardi MC; Surgo A; Zerella MA; Arculeo S; Fodor C; Ricotti R; Zampino MG; Ravenda S; Spinoglio G; Biffi R; Bazani A; Luraschi R; Vigorito S; Spychalski P; Orecchia R; Glynne-Jones R; Jereczek-Fossa BA
    Med Oncol; 2018 Mar; 35(5):59. PubMed ID: 29594584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
    Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.
    Ghareeb A; Paramasevon K; Mokool P; van der Voet H; Jha M
    Ann R Coll Surg Engl; 2019 Mar; 101(3):168-175. PubMed ID: 30482037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy.
    Ho KF; Marchant T; Moore C; Webster G; Rowbottom C; Penington H; Lee L; Yap B; Sykes A; Slevin N
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e375-82. PubMed ID: 22197229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
    Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
    Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
    Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):1943-8. PubMed ID: 27069184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
    Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer.
    Koeck J; Lohr F; Buergy D; Büsing K; Trunk MJ; Wenz F; Mai S
    Radiat Oncol; 2016 Apr; 11():53. PubMed ID: 27044498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.